As this was a new and reasonably successful attempt at treatment with VEGFR antagonist plus novel oral drug targeting pulmonary hypertension, ongoing research into similar cases should be carried out to verify the efficacy of this therapy. This evidence concerns the gene KDR and pulmonary arterial hypertension.